A novel electrical impedance function to estimate central aortic blood pressure waveforms

2021 ◽  
Vol 68 ◽  
pp. 102649
Author(s):  
Denesh Sooriamoorthy ◽  
S. Anandan Shanmugam ◽  
M.A. Juman
Keyword(s):  
Blood Pressure ◽  
Electrical Impedance ◽  
Impedance Function ◽  
Aortic Blood ◽  
Aortic Blood Pressure ◽  
Central Aortic Blood Pressure

The differential impact of aerobic and isometric handgrip exercise on blood pressure variability and central aortic blood pressure

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Maximilian Seidel ◽  
Nikolaos Pagonas ◽  
Felix S. Seibert ◽  
Frederic Bauer ◽  
Benjamin Rohn ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Blood Pressure Variability ◽  
Handgrip Exercise ◽  
Isometric Handgrip ◽  
Differential Impact ◽  
Aortic Blood ◽  
Isometric Handgrip Exercise ◽  
Aortic Blood Pressure ◽  
Central Aortic Blood Pressure

Abstract 16763: Unchanged Central Aortic Blood Pressure and Increased Myocardial Perfusion in Patients With Stable Coronary Artery Disease Receiving Ivabradine

Circulation ◽  
2015 ◽  
Vol 132 (suppl_3) ◽  
Author(s):  
Bernard I. Levy ◽  
Jean-Guillaume Dillinger ◽  
Patrick Henry ◽  
Damien Logeart ◽  
Stephane Manzo Silberman ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Heart Rate ◽  
Myocardial Perfusion ◽  
Beta Blocker ◽  
Central Blood Pressure ◽  
Pronounced Increase ◽  
Aortic Blood ◽  
Perfusion Time ◽  
Aortic Blood Pressure ◽  
Central Aortic Blood Pressure

Background: Treatment of hypertensive patients with beta-blockers reduces heart rate (HR) and increases central blood pressure, implying that the decrease in HR could explain reported increases in cardiovascular risk with beta-blocker. This analysis from a randomized, double-blind study explores whether HR reduction with the I f inhibitor ivabradine had an impact on central blood pressure and coronary perfusion. Methods and results: We included 12 normotensive patients with stable CAD, HR ≥70 bpm (sinus rhythm), and stable background beta-blocker therapy. Patients received ivabradine 7.5 mg bid or matched placebo for two 3-week periods with a crossover design and evaluation by aplanation tonometry. Treatment with ivabradine was associated with a significant reduction in resting HR after 3 weeks versus no change with placebo (-15.8±7.7 versus +0.3±5.8 bpm, p=0.0010). There was no relevant between-group difference in change in central aortic SBP (-4.0±9.6 versus +2.4±12.0 mm Hg, p=0.13) or augmentation index (-0.8±10.0% versus +0.3±7.6%, p=0.87). Treatment with ivabradine was associated with prolongation of diastolic perfusion time by 41% from baseline to 3 weeks (+215.6±105.3 versus -3.0±55.8 ms with placebo, p=0.0005) (Figure) and with a pronounced increase in an index of myocardial viability (Buckberg index, +39.3±27.6% versus -2.5±13.5% with placebo, p=0.0015). There were no safety issues during the study. Conclusion: Heart rate reduction with ivabradine does not modify central aortic blood pressure and is associated with a marked prolongation of diastolic perfusion time and an improvement in myocardial perfusion.

Sign in / Sign up

Export Citation Format

Share Document